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SUMMARY.-l. Mice have been completely protected against the lethal effects
ofrepeated injections of methotrexate by5-methyltetrahydrofolic acid. Metho-
trexate-resistant cells probably owe their resistance to their high content ofthis
substance.
2. Daily small doses were much more effective than fewer but larger doses.
3. The reduced efficiency-found in counteracting high dosages of metho-
trexate may be due to interference with folate transport across cell walls.
4. 5-Methyltetrahydrofolic acid and citrovorum factor did not differ greatly
intheirabilitytoinhibit methotrexatetoxicity. Itissuggestedthatthepharma-
ceutical effects of citrovorum factor are due to its conversion to 5-methyltetra-
hydrofolic acid.
ALTHOUGH methotrexate is a powerful inhibitor of malignant cell growth its
clinical use is restricted by its toxicity, the dose required for complete destruction
ofthe malignant cells usually being sufficient to destroy the host. Attempts have
beet made to improve its clinical effectiveness by using agents and modes oftreat-
ment which reduce the overall lethal effects while retaining the tumour inhibitory
properties. Of these, citrovorum factor (folinic acid; 5-formyltetrahydrofolic
acid; DL-5-formyl-5,6,7,8-tetrahydropteroyl-L-monoglutamic acid) has proved the
most useful. Combinations oflarge doses of methotrexate and citrovorum factor
give improved survival rates in leukaemic mice (Goldin, Venditti, Kline and
Mantel, 1966) and appear advantageous in the treatment of human tumours
(Schwarzenberg et al., 1969). Citrovorum factor is also used as an antidote for
methotrexate poisoning. The main storage form of folates in the body being
5-methyltetrahydrofolic acid (Blakley, 1969), it was anticipated that this com-
pound would have similar protective properties.
The cytotoxic effects ofmethotrexate havebeenpreviouslystudiedbyRueckert
and Mueller (1960) and O'Brien (1962). The conversion of deoxyuridylate to
thymidylate (for incorporation into DNA) utilises methylenetetrahydrofolate, and
the repletion ofthis pool offolate requires theproduction oftetrahydrofolic acid by
dihydrofolic acid reductase (Fig. 1). Methotrexate irreversibly inhibits the
reduction of dihydrofolic acid and thus depletes the cell store of tetrahydrofolic
acid. This inhibits synthesis of DNA since methylation of deoxyuridylate to
thymidylate no longer occurs (Osborn, Freeman and Huennekens, 1958; O'Brien,
1962). Since tetrahydrofolic acidis also converted (Fig. 2) to lO-formyltetrahydro-
folic acid which is required for purine biosynthesis, the cellular synthesis ofthese
compounds is also reduced (Blakley, 1969; Borsa and Whitmore, 1969).
52J. A.rBLAIR AND C. E. SEARLE
Dihydrofolic
acid
/ S
dihydrofolic
acid
reductase
Tetrahydrofolic >
acid
thymidylate -V DNA
deoxyuridylate
5,10-Methylene -
tetrahydrofolic acid
FiG. 1.-Utilisation of folates in DNA synthesis.
5-Formyl -
tetrahydrofolic acid
(citrovorumfactor)
10-Formyl- v
tetrahydrofolic acid 0
vj
Tetrahydrofolic acid
IV
I
5,10-Methenyl-
tetrahydrofolic acid
5,10 -Methylene -
tetrahycirofolic acid
U'
5-Methyl-
tetrahydrofolic acid
Fia. 2.-Utilisation of citrovorum factor in the cell folate cycle.
The citrovorum factor canenterthefolate metabolic cycledirectlywithoutprior
reduction by dihydrofolic acid reductase. Several routes are possible, but no
evidence is yet available to decide which are used. In all routes citrovorum factor
is converted to the 5,10-methenyl compound (Fig. 2, I). This is reduced (II) to
5,10-methylenetetrahydrofolic acid which is then available for the methylation of
deoxyuridylate (Fig. 1). The 5,10-methylene compound may be further reduced
(Fig. 2, III) to 5-methyltetrahydrofolic acid, which can be converted (IV) to tetra-
hydrofolic acid by vitamin B12demethylation. 5,10-Methenyltetrahydrofolic acid
is also hydrolysed (V) to 10-formyltetrahydrofolic acid, which loses the formyl
group in purine biosynthesis (VI) forming tetrahydrofolic acid (Blakley, 1969).
Irrespective ofthe route followed, citrovorum factor maintains the cell store of
tetrahydrofolates without utilisation of the dihydrofolic acid reductase pathway,
and thus allows synthesis ofDNA and purines in a cell in which the normal route is
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blocked by methotrexate. The effect of the citrovorum factor will be the same
whether it is administered before or after methotrexate. This bypassing of di-
hydrofolic acid reductase probably accounts for the reversal of the toxic effects of
methotrexate by the citrovorum factor.
A convenient synthesis of DL-5-methyltetrahydrofolic acid in good yield now
being available (Blair and Saunders, 1970), its effect on methotrexate toxicity in
mice has been studied. Since 5-methyltetrahydrofolic acid replenishes the tetra-
hydrofolate store within the cell by only one route (Fig. 2, IV), the relative effi-
ciencies of citrovorum factor and 5-methyltetrahydrofolic acid have also been
compared to elucidate the mode of action of the former.
EXPERIMENTAL
(fomnpounds
Mifethotrexate. For experiments i and ii (Table I) methotrexate sodium paren-
teral (Lederle Laboratories Division) was used after dilution to the appropriate
concentrations of methotrexate and NaCl. Subsequently, pure methotrexate
dihydrate (Lederle) was added to 0 9 per cent NaCl and dissolved by adding the
minimum amount ofsolid NaHCO3 (final pH approximately 8). Small amounts of
residual gelatinous material noticed in some samples were removed by filtration or
centrifugationi.
DL-5-Methyl-5,6,7,8-tetrahydrofolic acid.-This was synthetic material (Blair
and Saunders, 1970) which for the first tests was only available as the barium salt
(MTHF-Ba in tables). After this the calcium salt (MTHF-Ca) was employed
instead. Both were administered within an hour of dissolution in 0 9 per cent
NaCl.
Citrovorum factor.-This was used as a fresh solution of the calcium salt
(calcium leucovorin, Lederle) in 0 9 per cent NaCl.
All test solutions were administered subcutaneously with the dose per kg. body-
weight dissolved in 10 ml., i.e. the volume injected was 0Q3 ml. per 30 g. mouse.
Control mice received the same volume of saline solution.
Animnals
Male C57BL/Bcr X IF/Bcr F1 hybrid mice were used throughout. They were
lhoused in plastic (" Perspex ") boxes each containing 4 mice, and were fed cube diet
41B and tap water ad libitum.
Groups comprised 8 mice, each weighing 27-29 g. at the time of the first injec-
tions. They were weighed several times before starting the experiments, and daily
during the experiments. Deaths were also recorded daily. All mice which
survivedbeyondday 11 recovered, and werekilled 2-3 weeksafterthelastinjections.
In all experiments methotrexate was administered on 5 consecutive after-
noons (days 1-5), and the test compounds were injected 5 hours earlier into the
opposite flanks of the animals. The dosages and results obtained are summarised
in Table I. In some experiments (Table II) the test compounds were admini-
stered on one day or on three consecutive days only.
RESULTS
Toxicity of compounds
Calcium 5-mnethyltetrahydrofolate and citrovorum factor showed no toxic
effects at any dose used. Though the barium salt was also not toxic at doses
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sufficient to protect against methotrexate toxicity, single injections at 50 mg. per
kg. caused some paralysis ofthe hind-legs and diarrhoea. These effects were seen
after 15-30 minutes and lasted 2-3 hours.
The mice used here survived single injections of 100 and 200 mg. of metho-
trexate per kg. with only slight temporary loss of weight, but 5 consecutive daily
injections of 20 mg. per kg. resulted in the death ofnearly all the animals within a
few days ofthe last injections. The LD50 with this dose schedule lay between 10
and 15 mg. per kg. daily.
Inhibition of methotrexate toxicity by 5-methyltetrahydrofolic acid
A preliminary experiment (Table I, i) showed that 20 or 60 mg. of barium
methyltetrahydrofolate per kg. strongly protected mice against the toxicity of
TABLE I.-Effect of 5-Methyltetrahydrofolic Acid and Citrovorum Factor on the
Survival of Methotrexate-treated Mice: Inhibitor and Methotrexate Injected on
Days 1, 2, 3, 4 and 5
Dose
Test compound (mg./kg.)
(Control)
MTHF-Ba {20 60
(Control)
MTHF-Ba 3 3 10
L30
3
MTHF-Ca 3
3
(Control)
MTHF-Ca . 5
Citrovorum-Ca . 5
(Control)
F 037
MTHF-Ca 1.1
10
0*37.
Citrovorum-Ca 1.:
10
(Control)
r10
MTHF-Ca . 20
L40
r10
Citrovorum-Ca . 20
L40
Methotrexate
dose
(mg./kg.)
20
20
20
20
20
20
20
20
25
50
100
50
50
50
25
25
25
25
25
25
25
25
25
100
100
100
100
100
100
100
Fall in
Survivors av. wt.
at 14 days Mice dead ondays: (g.)
1 . 6, 8, 8, 8, 8, 8, 8 . 8-5
8 . . 1.5
8 . . 3.5
2 . 8,8,8,8,9,9 . 7
6 .8,8 . 3
8 . . 0.5
8 . - . 05
8 . .1
8 . 05
7 .9 .3
0 . 6,7,7,7,7,7,8,8. 8
0 .6, 7, 7, 7, 7, 7, 8,8. 9
3 . 7,8,8,8,8 . 5
8 . .3
0 . 7,7,7,7,7,7,7,8. 8
2 . 7, 8, 8, 9, 9, 10 . 8
7 .8 .2
8 . .1
8 . .0
0 . 6,7,7,7,8,8,8,9. 7
8 . .3
8 . .1
8 . .0
0 . 6,6,6,6,6,6,6,6. 8
0 . 6,8,8,8,8,8,9,9. 7
6 .9,9 . 5
6 .9, 10 . 4
1 . 7, 8, 8, 9, 9, 9, 9 . 6 5
7 .8 . 3.5
7 .8 .4
5 daily injections ofmethotrexate (20 mg. per kg.) when given 5 hours before each
injection; deaths were reduced from 7/8 in the control mice to 0/8 in each ofthe test
groups. While control mice dropped over 8 g. in weight before dying between
5 and 7 days after the first treatment with methotrexate, mice on the lower dose of
5-methyltetrahydrofolic acid dropped only 1*5 g. and then recovered. A rather
Expt
i1
11
iii
iv
V
vi
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larger drop of 3-5 g. at the higher dose is attributed to the toxicity of the barium
salt used here.
Subsequent experiments (ii, iii, v) showed that as little as 1 mg. of 5-methyl-
tetrahydrofolic acid per kg. gave appreciable protection against methotrexate at 20
or 25 mg. per kg., while 3 mg. per kg. was completely protective.
When the daily dose of methotrexate was doubled to 50 mg. per kg. (iii, iv),
5-methyltetrahydrofolic acid at 3 or 5 mg. per kg. still gave appreciable but not
complete protection. With a further doubling to 100 mg. of methotrexate per kg.
(vi), however, some deaths still occurred even with 20 or 40 mg. of 5-methyltetra-
hydrofolic acid per kg.
Comparison of inhibitory effect with citrovorum factor
Direct comparisons have been made between the inhibitory effects of 5-methyl-
tetrahydrofolic acid and citrovorum factor, each administered as the calcium salt
under the same conditions.
The first comparison (TableI, iv) indicated that the 5-methyl compound afforded
the mice appreciably less protection than did the same dose of citrovorum factor.
Experiment vi, using large doses of inhibitors and methotrexate, led to a similar
conclusion when based on the number of mice surviving, though at the two higher
levels ofinhibitor deaths occurred 1-2 days earlier in citrovorum-treated mice. With
very small levels of inhibitor (0.37 mg. per kg.; expt. v) 5-methyltetrahydrofolic
acid was slightly more effective than citrovorum factor.
It is concluded that these two 5-substituted tetrahydrofolic acids do not differ
greatly in their ability to counteract the toxicity of methotrexate under the condi-
tions used here.
Effect of less frequent 5-methyltetrahydrofolic acid injections
In some further experiments the inhibitory effect of a single injection, or of
three consecutive daily injections, of this compound has been investigated.
The first test (Table II, i) showed that, although 3 mg. of 5-methyltetra-
hydrofolic acid per kg. daily protects mice strongly against 25 or 50 mg. of metho-
TABLEII.-Effect of 5-Methyltetrahydrofolic Acid on the Survival of Methotrexate-
treated Mice when Administered on 1 or 3 Days of Methotrexate Treatment only
Dose of Methotrexate Fall in
MTHF-Ca Injected dose Survivors av. wt
Expt (mg./kg.) on day(s): (mg./kg.) at 14 days Mice dead on days: (g.)
i 15
. 5
. 25 . 3 .7,7,8,8,8 . 7
15
. 5 . 50 . 0 . 7, 7, 7, 7, 7,7, 8,8 . 7
15
. 5
. 100 . 0 . 5, 6, 6, 7,7,8,8,8 . 8
ii (Control)
- . 50 . 0 . 6, 7, 7, 7, 7,8,8,9 . 10
50
. 1 . 50 1 7, 8, 8,8,9,9,10 6
50 . 2 . 50 . 2 . 7,9,9,9,9,10 . 5-5
50
. 3 . 50 . 3 . 9, 9,10,10,10 6
50 . 4 . 50 . 1 . 7,7,7,7,8,8, 11 8.5
50 0 . 0 . 6, 6, 7, 7,8,8,8,10 5
iii
. (Control)
. . 50 . 0 . 6, 7, 7, 7,7,7,8,8 . 9
15
. 1, 2,3 . 50 . 1 . 7, 7, 7,8,8,9,11 5
15 . 2, 3,4 . 50 . 1 . 6, 8, 8,8,8,8,11 6-5
15
. 3, 4,5 . 50 . 5 . 7, 7,9 7
15 . 4, 5,6 . 50 . 1 . 6, 7, 7, 7,7,7,7 . 5.5
15
. 5, 6,7 . 50 . 0 . 6, 6, 6, 6, 7,7,7,8 . 9
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trexate per kg., the same total amount of inhibitor given on day 5 only had very
little protective effect. Even with the dose ofinhibitor increased to 50 mg. per kg.
(ii) the protective effect was still small; the maximum survival (3/8) occurred with
administration on day 3.
With three consecutive daily doses of 15 mg. per kg. (iii), the protective effect
of 5-methyltetrahydrofolic acid was greatest (5/8 survivors) when given on days
3, 4 and 5 ofmethotrexate administration. Injections starting on days 1, 2, 4 or 5
failed to save more than 1 out of 8 animals.
Reduction in the frequency of 5-methyltetrahydrofolic acid administration
thus greatly reduces its protective effect against methotrexate toxicity.
DISCUSSION
The highest dihydrofolic acid reductase levels in the mouse, found in the liver,
kidney and intestinal mucosa, are under 10-6 moles per kg. body-weight (Werk-
heiser, 1961). Methotrexate binds stoichiometrically to the enzyme (Werkheiser,
1961), and each single daily dose ofmethotrexate at 20 mg. (about 5 x 10-5 moles)
per kg. therefore greatly exceeds the enzyme equivalent with consequent de-
activation of tissue dihydrofolic acid reductase.
The above experiments have shown that relatively small daily amounts of
5-methyltetrahydrofolic acid give complete protection, as judged by survival and
body-weight, against lethal doses ofmethotrexate (Table I, i, ii, iii). This protec-
tive action is attributed to direct conversion and utilisation of the 5-methyl
compound without involvement of dihydrofolic acid. It also indicates that
methotrexate-resistant normal and malignant rat cells owe their resistance to the
large amounts of 5-methyltetrahydrofolic acid which they contain (Sotobayashi,
Rosen and Nichol, 1966).
With larger doses of methotrexate the protective effect of small doses of
5-methyltetrahydrofolic acid was reduced or abolished (Table I, iii), but was
restored to some extent with increased doses ofthe 5-methyl compound (vi). This
may indicate competition between 5-methyltetrahydrofolic acid and methotrexate
for an enzyme, or for a transport mechanism across cell walls such as that demon-
strated for methotrexate, folic acid, citrovorum factor and 5-methyltetrahydrofolic
acid in the L1210 leukaemic cell (Goldman, Lichtenstein and Oliverio, 1968;
Goldman, 1969; Lichtenstein, Oliverio and Goldman, 1969).
Delayed doses of 5-methyltetrahydrofolic acid afforded considerably reduced
protection. A single dose of50 mg. per kg. resulted in a maximum of3/8 survivors
when administered on day 3 to mice given 5 daily doses ofmethotrexate at 50 mg.
per kg. (Table II, ii). Three consecutive daily doses of 15 mg. per kg. gave most
protection (5/8 survivors) when given on days 3, 4 and 5 of methotrexate admini-
stration (Table II, iii).
When citrovorum factor and 5-methyltetrahydrofolic acid were compared in
their ability to reverse the toxicity of methotrexate there appeared to be little
difference (Table I, iv, v, vi), suggesting that they both act by a common pathway.
Since citrovorum factor may be converted to 5-methyltetrahydrofolic acid (Fig. 2,
I-III) but not vice versa, its pharmaceutical effects are probably due to this
conversion.
Preliminary experiments in mice bearing the R1 lymphoma have been kindly
carried out by Dr. T. A. Connors ofthe Chester Beatty Research Institute. These
have shown that large doses of5-methyltetrahydrofolic acid do not affect growth of
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the tumour, and that, at doses of methotrexate at which the animal succumbs to
drug toxicity, combinations ofmethotrexate and 5-methyltetrahydrofolic acidgive
improved survival times. Further experiments are in progress.
We are grateful to Lederle Laboratories Ltd. for supplying pure methotrexate
powder and the calcium salt ofcitrovorum factor. We also thankthe Birmingham
Branch ofthe British Empire Cancer Campaign for Research for financial support.
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